TACE + SBRT for Liver Cancer
(TACE Trial)
Trial Summary
What is the purpose of this trial?
Trans-arterial chemoembolization (TACE) is a standard treatment for patients with hepatocellular carcinoma (also called liver cancer). This is where chemotherapy is injected into the arteries of the liver and liver cancer. Unfortunately, the tumour grows after TACE in many patients. A new treatment using a specialized radiation procedure called Stereotactic ablative body radiotherapy (SBRT) may increase the chance to control liver cancer. SBRT allows radiation treatments to be focused more precisely, and be delivered more accurately than with older treatments. The purpose of this study is to find out if TACE alone versus TACE plus SBRT is better for you and your liver cancer.
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications. However, chemotherapy must be completed at least 2 weeks before starting radiation therapy or TACE, and it should not be planned for at least 1 week after treatment (4 weeks for certain drugs).
What data supports the effectiveness of the treatment TACE + SBRT for liver cancer?
Research shows that combining TACE (a procedure that blocks blood supply to the tumor) with SBRT (a precise form of radiation therapy) can improve survival rates for patients with liver cancer that cannot be surgically removed. Studies indicate that this combination may be more effective than using SBRT alone.12345
Is the combination of TACE and SBRT safe for liver cancer treatment?
Research shows that combining TACE (a procedure that blocks blood supply to a tumor) and SBRT (a precise form of radiation therapy) is generally safe for treating liver cancer, with few major complications. However, there can be rare biliary (related to bile ducts) complications following TACE.46789
How is the TACE + SBRT treatment for liver cancer different from other treatments?
The TACE + SBRT treatment for liver cancer is unique because it combines two approaches: TACE, which delivers chemotherapy directly to the liver tumor through the blood vessels, and SBRT, a precise form of radiation therapy that targets the tumor with high doses of radiation. This combination aims to enhance tumor control and improve survival in patients with liver cancer that cannot be surgically removed.124810
Research Team
Michael Lock, M.D.
Principal Investigator
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Eligibility Criteria
This trial is for adults with liver cancer, having up to 5 liver lesions and no severe cirrhosis or active hepatitis. They must not have had certain treatments recently, be able to use contraception, and have a life expectancy over 6 months. Those with larger tumors or previous radiation in the same area can't join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Transarterial Chemoembolization (TACE) or TACE plus Stereotactic Body Radiation Therapy (SBRT)
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Stereotactic Body Radiation Therapy
- Transarterial Chemoembolization
Transarterial Chemoembolization is already approved in United States, China, European Union for the following indications:
- Non-small cell lung cancer
- Lung metastases
- Unresectable lung cancer
- Advanced lung cancer
- Non-small cell lung cancer
- Lung metastases
Find a Clinic Near You
Who Is Running the Clinical Trial?
London Health Sciences Centre OR Lawson Research Institute of St. Joseph's
Lead Sponsor
London Health Sciences Centre Research Institute and Lawson Research Institute of St. Joseph's
Lead Sponsor
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead Sponsor
Lawson Health Research Institute
Lead Sponsor
CancerCare Manitoba
Collaborator